Treatments
TL;DR: 36 FDA-approved drugs have labels that mention multiple myeloma in their indications. Grouped below by mechanism of action. This list gives you the vocabulary — your oncologist chooses a regimen based on your specific subtype, stage, biomarkers, and prior therapies.
Source: OpenFDA drug label API · last checked
Cost transparency
Drugs below have published Medicare Part B or Part D spending figures — what the federal government actually paid per beneficiary in 2023.
Figures are average Medicare spending per beneficiary. Out-of-pocket varies by insurance and manufacturer assistance. See all drug costs →
Monoclonal antibodies and antibody-drug conjugates (ADCs) that bind specific proteins on cancer cells.
SLAMF7-directed Immunostimulatory Antibody [EPC] · SLAMF7-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE • EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. • EMPLICITI is indicated in combin…
CD38-directed Cytolytic Antibody [EPC] · CD38-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE SARCLISA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasom…
Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager [EPC] · B Cell Maturation Antigen-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE LYNOZYFIC is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory ag…
Therapies using genetically modified or harvested cells — CAR-T, TIL therapy, and related cellular treatments.
From the FDA label: 1 INDICATIONS AND USAGE CARVYKTI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory age…
From the FDA label: 1 INDICATIONS AND USAGE ABECMA is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-C…
Cytotoxic drugs that kill rapidly dividing cells. Includes platinums, taxanes, antimetabolites, alkylators, topoisomerase inhibitors, and anthracyclines.
From the FDA label: 1 INDICATIONS AND USAGE Cyclophosphamide for injection is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type ly…
From the FDA label: 1 INDICATIONS AND USAGE Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: • Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type
From the FDA label: 1 INDICATIONS AND USAGE Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: • malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphoc…
From the FDA label: 1 INDICATIONS AND USAGE Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: Ovarian cancer : After failure of platinum-based chemotherapy ( 1.1 ) AIDS-related Kaposi’s Sarcoma : After fail…
From the FDA label: 1 INDICATIONS AND USAGE Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer: After failure of platinum-based chemotherapy ( 1.1 ) • AIDS-related Kaposi’s Sarcoma: After fa…
Drugs that block hormone-driven cancer growth (aromatase inhibitors, SERMs, androgen receptor blockers, GnRH analogs).
Corticosteroid [EPC] · Corticosteroid Hormone Receptor Agonists [MoA]
From the FDA label: 1 INDICATIONS AND USAGE HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM). HEMADY is a corticosteroid indicated in combination with other anti-myeloma products for the…
Drugs whose pharmacologic class was not automatically classified into the groups above. Check the FDA label for mechanism details.
From the FDA label: 1 INDICATIONS AND USAGE BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including
Proteasome Inhibitor [EPC] · Proteasome Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Bortezomib for injection is a proteasome inhibitor indicated for: • treatment of adult patients with multiple myeloma ( 1.1 ) • treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Borte…
Proteasome Inhibitor [EPC] · Proteasome Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Kyprolis is a proteasome inhibitor that is indicated: for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with Lenalidomide
From the FDA label: 1 INDICATIONS AND USAGE Carmustine for injection, USP is indicated as palliative therapy as a single agent or in established combination therapy in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ep…
CD38-directed Cytolytic Antibody [EPC] · CD38-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE DARZALEX is indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant a…
CD38-directed Cytolytic Antibody [EPC] · Endoglycosidase [EPC]
From the FDA label: 1 INDICATIONS AND USAGE DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bor…
RANK Ligand Inhibitor [EPC] · RANK Ligand Blocking Activity [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Bomyntra is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults a…
RANK Ligand Inhibitor [EPC] · RANK Ligand Blocking Activity [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Osenvelt is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults a…
RANK Ligand Inhibitor [EPC] · RANK Ligand Blocking Activity [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Aukelso is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults an…
RANK Ligand Inhibitor [EPC] · RANK Ligand Blocking Activity [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Xtrenbo is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults an…
From the FDA label: 1 INDICATIONS AND USAGE ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory age…
From the FDA label: 1 INDICATIONS AND USAGE NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a proteasome inhibitor indicated in…
Thalidomide Analog [EPC]
From the FDA label: 1 INDICATIONS AND USAGE Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-…
From the FDA label: 1 INDICATIONS AND USAGE Evomela is an alkylating drug indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. ( 1.1 ) 1.1 Multiple Myeloma-Cond…
From the FDA label: 1 INDICATIONS AND USAGE Multiple Myeloma-Palliative Treatment IVRA is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. IVRA is an alkylating drug indicated for palliative tre…
From the FDA label: INDICATIONS AND USAGE Melphalan Hydrochloride for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
From the FDA label: 1 INDICATIONS AND USAGE APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APH…
From the FDA label: INDICATIONS AND USAGE Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases.
Hematopoietic Stem Cell Mobilizer [EPC]
From the FDA label: 1 INDICATIONS AND USAGE Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma…
Thalidomide Analog [EPC]
From the FDA label: 1 INDICATIONS AND USAGE Pomalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients: in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapie…
From the FDA label: 1 INDICATIONS AND USAGE TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent…
From the FDA label: 1 INDICATIONS AND USAGE TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma in combination with daratumumab and hyaluronidase-fihj in patients who have received at least one prior line of t…
From the FDA label: 1 INDICATIONS AND USAGE • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestati…
From the FDA label: INDICATIONS AND USAGE a) Acute Nonlymphocytic Leukemias TABLOID brand Thioguanine is indicated for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias. However, it is not recommended for use during ma…
From the FDA label: 1 INDICATIONS AND USAGE Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1) Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conju…
Disease foundations below have active funds covering multiple myeloma medications. Manufacturer patient-assistance programs are listed on each drug's cost page.
copay, premium, and deductible assistance for insured patients; fund availability varies by disease
https://www.healthwellfoundation.org/disease-funds/Funds open and close based on availability; check disease-funds page for current status
copay assistance for 20+ cancer types via disease-specific funds
https://www.panfoundation.org/find-disease-fund/Merging with Patient Advocate Foundation; unified 'TotalAssist' program launches 2026-07-01
direct copay / coinsurance assistance via disease-specific funds
https://copays.org/Merging with PAN Foundation; launching 'TotalAssist' 2026-07-01
copay assistance for chemotherapy and targeted treatment medications
https://www.cancercare.org/copayfoundationlimited financial assistance for transportation, home care, child care, and treatment-related costs
https://www.cancercare.org/financialTrials test new therapies before they are FDA-approved. Often a way to access tomorrow's drugs today.
Back to Multiple Myeloma hub →Stats, second opinions, NCI cancer centers, oncologists.
Understand biomarkers →Most targeted therapies require biomarker testing. Here's what you need to know.
Read your pathology report →Which drugs apply to you depends on what's in your pathology.